StemoniX Collaborates with Atomwise to Form a Joint Venture Targeting Rett Syndrome

 StemoniX Collaborates with Atomwise to Form a Joint Venture Targeting Rett Syndrome

StemoniX Collaborates with Atomwise to form Joint Venture Targeting Rett Syndrome

Shots:

  • Joint Venture will combine StemoniX’s human microOrgan platform with Atomwise’s AI technology to allow the rapid discovery and development of novel therapies, initially targeting Rett syndrome
  • Atomwise will utilize its AI technology for identifying potent and selective binders for protein targeting Rett syndrome while StemoniX will test the compounds on its human microBrain 3D disease model to determine the biological efficacy
  • The JV will speed up the drug discovery process as their expertise will enable drug discovery on historically undruggable targets and provide new opportunities for Rett Syndrome

Click here to­ read full press release/ article | Ref: PRNewswire | Image:  Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post